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Transformative Companies  
Enabled by Nanotechnology 
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SAFE HARBOR STATEMENT 
This presentation may contain statements of a forward-looking nature 
relating to future events. Statements contained in this presentation that are 
forward-looking statements are intended to be made pursuant to the Safe 
Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  
These forward-looking statements are subject to the inherent uncertainties in 
predicting future results and conditions.  These statements reflect the 
Company’s current beliefs, and a number of important factors could cause 
actual results to differ materially from those expressed herein.   
 
Please see the Company’s Annual Report on Form 10-K, as well as subsequent 
filings, filed with the Securities and Exchange Commission for a more detailed 
discussion of the risks and uncertainties associated with the Company’s 
business, including but not limited to the risks and uncertainties associated 
with venture capital investing and other significant factors that could affect 
the Company’s actual results.  Except as otherwise required by Federal 
securities laws, Harris & Harris Group, Inc. undertakes no obligation to update 
or revise these forward-looking statements to reflect new events or 
uncertainties. 
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INVESTING EXCLUSIVELY IN  
NANOTECHNOLGOY SINCE 2002 
WE HAVE A PIPELINE OF  
PORTFOLIO COMPANIES 
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Cleantech Healthcare Electronics 
Early Stage 
Laser Light Engines 
Produced Water Absorbents 
Nextreme 
Ultora 
Ancora 
Enumeral 
Mid Stage 
Cobalt 
Contour Energy 
ABSMaterials 
Mersana 
Ensemble 
Champions Oncology 
Adesto 
SiOnyx 
D-Wave Systems 
Nantero 
Cambrios 
Kovio 
Late Stage 
Solazyme (NASDAQ:SZYM) 
Bridgelux 
Innovalight(1) 
Nanosys 
Metabolon 
Xradia 
NeoPhotonics  (NYSE:NPTN) 
Molecular Imprints 
Realized Positive 
Exits 
 
Siluria 
 
BioVex(2) 
Note:  Portfolio companies and stage classifications as of June 30, 2011.  Table does not include portfolio companies  
 valued at $0 as of June 30, 2011. 
(1)   Innovalight was acquired by DuPont on July 21, 2011 
(2)   A portion of the potential amount we will receive from the sale of BioVex remains unrealized as of 
 June 30, 2011.   
NanoGram Devices 
OUR PARTNERS 
Note: All numbers are as of March 31, 2011. 5 
Over $80 million  
in federal funding 
Over two thirds have 
significant corporate 
partnerships or investors 
> $1 billion in capital from 
other venture capital firms 
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$126 million  
Invested by  
H&H 
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WE WERE EARLY INVESTORS IN  
TODAY’S GROWTH MARKETS 
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2003 2004 2006 2001 2007 2008 2009 2010 2002 2005 
Cancer Therapeutics – Biologics 
 
 
 
Disease free at 4 years 
(Acq. By Amgen) 
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TRENDS IN NANOMEDICINE 
MEDICINE 
Materials 
Science 
Chemistry 
Electronics 
Physics 
Orthobiologics 
Biological NanoMechanics 
Wound Care 
New Classes of Therapeutics 
Antibody Engineering 
Diagnostics Tools 
Healthcare Sensors 
Imaging 
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TRENDS IN NANOMEDICINE 
1. 3D Biology 
 Limitations of 2D models for drug development. 
2. Molecular Engineering 
 Engineering proteins and small molecules to enable new 
classes of compounds. 
3. Personalized Medicine 
 Trends in molecular diagnostics. 
4. Cellular Therapy 
 Trends in stem cell therapy. 
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OUR HEALTHCARE PORTFOLIO 
Acquired by Amgen: up to $1 billion 
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